RET and medullary thyroid gland carcinoma: The results of our study provide support to the recommendation that RET genetic screening should be performed in all MTC cases, regardless of the family history of patients and their clinical presentation, and according to the appropriateness of ATA’s guidelines for clinical management of carriers of MOD risk level mutations.